section-209-glp-1-receptor-agonists-cbs-psp

📖 Wiki Page

therapeutic2422 wordssynced 2026-04-02

Section 209: GLP-1 Receptor Agonists for CBS/PSP

...

Section 209: GLP-1 Receptor Agonists for CBS/PSP

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">section-209-glp-1-receptor-agonists-cbs-psp</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>GLP-1 analog[@j2024]</td>
</tr>
<tr>
<td class="label">Tirzepatide</td>
<td>GLP-1/GIP dual</td>
</tr>
<tr>
<td class="label">Lixisenatide</td>
<td>GLP-1 analog</td>
</tr>
<tr>
<td class="label">Liraglutide</td>
<td>GLP-1 analog</td>
</tr>
<tr>
<td class="label">Dulaglutide</td>
<td>GLP-1 Fc fusion</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Week 1-2</td>
<td>0.25 mg</td>
</tr>
<tr>
<td class="label">Week 3-4</td>
<td>0.5 mg</td>
</tr>
<tr>
<td class="label">Week 5-8</td>
<td>1.0 mg</td>
</tr>
<tr>
<td class="label">Week 9-12</td>
<td>1.5 mg</td>
</tr>
<tr>
<td class="label">Maintenance</td>
<td>1.0-2.0 mg</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Week 1</td>
<td>0.6 mg</td>
</tr>
<tr>
<td class="label">Week 2-3</td>
<td>1.2 mg</td>
</tr>
<tr>
<td class="label">Week 4+</td>
<td>1.2-1.8 mg</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Week 1</td>
<td>10 μg</td>
</tr>
<tr>
<td class="label">Week 2+</td>
<td>20 μg</td>
</tr>
<tr>
<td class="label">Current Med</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Levodopa</td>
<td>No direct interaction</td>
</tr>
<tr>
<td class="label">Rasagiline (MAO-B)</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Pramipexole</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">Amantadine</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">Entacapone</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">COMT inhibitors</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">SSRI/SNRI</td>
<td>Theoretical serotonin syndrome</td>
</tr>
<tr>
<td class="label">Anticoagulants</td>
<td>No direct interaction</td>
</tr>
<tr>
<td class="label">NSAIDs</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">PPI</td>
<td>No interaction</td>
</tr>
<tr>
<td class="label">Measure</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">PSP Rating Scale (PSPRS)</td>
<td>Quarterly</td>
</tr>
<tr>
<td class="label">Unified Parkinson's Disease Rating Scale (UPDRS) Part III</td>
<td>Quarterly</td>
</tr>
<tr>
<td class="label">Timed Up and Go (TUG)</td>
<td>Monthly</td>
</tr>
<tr>
<td class="label">Gait analysis</td>
<td>6 months</td>
</tr>
<tr>
<td class="label">Measure</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">MoCA</td>
<td>Quarterly</td>
</tr>
<tr>
<td class="label">Trail Making Test A/B</td>
<td>Quarterly</td>
</tr>
<tr>
<td class="label">Executive function battery</td>
<td>6 months</td>
</tr>
<tr>
<td class="label">Measure</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">ADL scale</td>
<td>Quarterly</td>
</tr>
<tr>
<td class="label">Falls diary</td>
<td>Ongoing</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Baseline</td>
</tr>
<tr>
<td class="label">HbA1c</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Fasting glucose</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Insulin</td>
<td>✓</td>
</tr>
<tr>
<td class="label">HOMA-IR</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Weight</td>
<td>✓</td>
</tr>
<tr>
<td class="label">Marker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">NfL (Neurofilament Light)</td>
<td>Plasma</td>
</tr>
<tr>
<td class="label">Total tau</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Phospho-tau181</td>
<td>Plasma</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>20-30%</td>
</tr>
<tr>
<td class="label">Vomiting</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Diarrhea</td>
<td>10-15%</td>
</tr>
<tr>
<td class="label">Constipation</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Hypoglycemia</td>
<td><5%</td>
</tr>
<tr>
<td class="label">Injection site reactions</td>
<td><5%</td>
</tr>
<tr>
<td class="label">Primary Therapy</td>
<td>Add-on</td>
</tr>
<tr>
<td class="label">GLP-1 agonist</td>
<td>Omega-3</td>
</tr>
<tr>
<td class="label">GLP-1 agonist</td>
<td>Vitamin D</td>
</tr>
<tr>
<td class="label">GLP-1 agonist</td>
<td>Exercise</td>
</tr>
<tr>
<td class="label">GLP-1 agonist</td>
<td>Sulforaphane</td>
</tr>
</table>

Overview

Mermaid diagram (expand to render)

This section provides advanced clinical implementation protocols for GLP-1 receptor agonist therapy in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). While general GLP-1 neuroprotection is covered in [Section 115: GLP-1 Receptor Agonists](treatments/glp-1-receptor-agonists), this section focuses on CBS/PSP-specific protocols, patient selection, drug interactions, and clinical outcome monitoring.

The rationale for GLP-1 targeted therapy in CBS/PSP is particularly strong because:

4R-tau aggregation is the core pathological feature in both conditions
GLP-1 signaling directly reduces tau phosphorylation and aggregation
Neuroinflammation is a major driver of disease progression — GLP-1 has potent anti-inflammatory effects
Metabolic dysfunction (insulin resistance, dyslipidemia) is common in CBS/PSP and can be addressed
Existing medications (levodopa, rasagiline) can be continued alongside GLP-1 therapy
The MOST-ABLE trial demonstrated motor and cognitive benefits in PSP patients

1. Mechanism of Action in CBS/PSP

1.1 Neuroprotective Pathways

GLP-1 receptor activation provides multiple neuroprotective effects relevant to CBS/PSP pathology:

Tau Pathology Modulation:

Inhibition of GSK-3β activity → reduced tau phosphorylation at multiple sites (Ser396, Thr231, AT8)
Enhanced autophagy flux → increased clearance of phosphorylated tau species
Reduced tau aggregation through stabilization of microtubule-associated proteins
Protection against tau-induced synaptic dysfunction

Neuroinflammation Reduction:

Suppression of microglial activation markers (Iba-1, CD68)
Reduced pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
Inhibition of NF-κB signaling cascade
Modulation of astrocyte reactivity

Metabolic Effects:

Improved insulin sensitivity in the brain
Enhanced glucose utilization in neurons
Reduced systemic inflammation via peripheral mechanisms
Potential weight management benefits

Synaptic Protection:

Preservation of dendritic spine density
Enhancement of long-term potentiation
Protection against excitotoxicity
Support of mitochondrial function

1.2 Why CBS/PSP Patients May Respond Particularly Well

CBS and PSP patients often show:

Metabolic comorbidity: Many patients develop insulin resistance; GLP-1 agonists address this

Prominent neuroinflammation: Strong anti-inflammatory effects of GLP-1 therapy

Tau-predominant pathology: Direct effects on tau phosphorylation and clearance

Limited treatment options: Disease-modifying therapies are urgently needed

Younger age at onset (particularly CBS): May respond better to metabolic therapy

2. Clinical Implementation of GLP-1 Agonists

2.1 Agent Selection for CBS/PSP

Recommendation for CBS/PSP:

First choice: Semaglutide (best balance of efficacy and tolerability)
Alternative: Liraglutide (more data in neurodegenerative disease)
Dual agonist option: Tirzepatide (if available and tolerated)

2.2 Semaglutide Protocol

Dosing Schedule: Administration:

Subcutaneous injection in abdomen, thigh, or upper arm
Take at consistent time each week
Can be taken with or without food
Store refrigerated (2-8°C)

Monitoring Requirements:

Blood glucose (especially if diabetic)
Body weight weekly
GI symptom tracking
Blood pressure (can cause transient increase)

2.3 Liraglutide Protocol

Dosing Schedule: Administration:

Subcutaneous injection, preferably evening
Rotate injection sites
Take at similar time each day

2.4 Lixisenatide Protocol (Daily Option)

Dosing Schedule: Advantages:

Higher BBB penetration (shorter half-life)
More flexible dose adjustment
Useful for patients with GI sensitivity to weekly formulations

3. Patient-Specific Protocol

3.1 50-Year-Old Male, CBS/PSP Differential

Patient Characteristics:

Age: 50 years (younger, potentially more responsive to metabolic therapy)
Diagnosis: CBS/PSP differential
Alpha-synuclein: Negative (suggests tau-predominant pathology)
Current medications: Levodopa, Rasagiline

Therapeutic Rationale:

This patient profile is particularly suitable for GLP-1 therapy because:

Younger age → better metabolic response potential

Tau-predominant pathology → direct anti-tau effects of GLP-1

Already on neuroprotective medications (rasagiline) → potential synergy

No significant GI issues reported → good tolerability expected

Recommended Protocol:

Option A: Semaglutide (Preferred)

Week 1-2: 0.25 mg weekly
Week 3-4: 0.5 mg weekly
Week 5-8: 1.0 mg weekly
Continue 1.0-1.5 mg weekly long-term

Option B: Liraglutide (Alternative)

Week 1: 0.6 mg daily
Week 2-3: 1.2 mg daily
Continue 1.2-1.8 mg daily long-term

Integration with Current Medications:

3.2 Dose Modification for Comorbidities

For Type 2 Diabetes:

Start at lowest dose (0.25 mg semaglutide)
Monitor glucose more closely
May need to adjust diabetes medications
Target: HbA1c 7-7.5% (avoid hypoglycemia)

For Cardiovascular Disease:

No specific contraindication (cardiovascular benefits documented)
Monitor blood pressure
Watch for heart rate changes

For Renal Impairment:

Mild-moderate: No dose adjustment needed
Severe: Use with caution, start low

For Hepatic Impairment:

Mild-moderate: No specific adjustment
Severe: Limited data — use with caution

4. Drug Interactions

4.1 Critical Interactions for CBS/PSP Patients

With Levodopa:

No direct pharmacokinetic interaction
Separate administration times for optimal absorption
GLP-1 can be taken in the morning, levodopa with meals
Monitor for hypotension if autonomic function affected

With Rasagiline (MAO-B Inhibitor):

No significant interaction
Both can be continued safely
Watch for serotonin syndrome if other serotonergic drugs added (theoretical risk)
Avoid meperidine (contraindicated with rasagiline)

With Other Parkinson's Medications:

With Common CBS/PSP Adjunct Therapies:

4.2 GLP-1 Specific Drug Interactions

Drugs that may enhance GLP-1 effects:

Other incretin-based therapies ( DPP-4 inhibitors) — may enhance glucose-lowering
Thyroid medications (thyroxine) — may affect absorption

Drugs that may reduce GLP-1 effects:

Corticosteroids — may reduce efficacy
Atypical antipsychotics — may cause weight gain

Important Considerations:

Oral medications may have delayed absorption due to GLP-1 induced gastric emptying
Consider timing of other oral medications (take 1+ hour before or after GLP-1)

5. NET (Negative Equilibration Test) Protocol

5.1 Assessment Rationale

The NET assesses vestibular compensation and white matter function, particularly relevant for CBS/PSP patients:

Vertical gaze palsy (PSP): NET can objectify oculomotor deficits
Balance dysfunction: Assesses compensation mechanisms
Postural instability: Quantifies response to therapy
Disease progression: Tracks changes over time

5.2 Implementation

Procedure:

Patient positioned at 45-degree angle

Video-oculography recording during:

Horizontal head turns (VOR gain assessment)
Vertical head turns
Optokinetic stimulation

3. Duration: 15-20 minutes

Pre-Treatment Baseline:

Document horizontal and vertical VOR gains
Assess saccadic velocities
Note presence of square-wave jerks

Monitoring Schedule:

Baseline: Before initiating GLP-1 therapy
12 weeks: Early response assessment
24 weeks: Intermediate response
48 weeks: Long-term response

Interpretation:

Stable or improved VOR gains → therapeutic benefit
Declining gains → disease progression
Changes in saccadic accuracy → CNS effect

6. Assessment and Monitoring

6.1 Clinical Outcome Measures

Motor Assessment: Cognitive Assessment: Functional Assessment:

6.2 Biomarker Monitoring

Metabolic Markers: Neurodegeneration Markers: Target Outcomes:

NfL: Stable or decreasing (indicates reduced neurodegeneration)
Metabolic: Improved insulin sensitivity
Motor: Stable or improved PSPRS/UPDRS scores

6.3 Safety Monitoring

GLP-1 Specific Adverse Events:

Red Flags:

Persistent severe GI symptoms
Pancreatitis symptoms (severe abdominal pain)
Signs of thyroid C-cell tumor (rare)

7. Combination Therapy Integration

7.1 Synergistic Combinations

7.2 Integration with Other Sections

GLP-1 therapy integrates with other CBS/PSP treatment sections:

[Section 201: Mitochondrial Biogenesis](/therapeutics/section-201-mitochondrial-biogenesis-pgc1alpha-cbs-psp) — Metabolic support
[Section 203: Epigenetic Therapy](/therapeutics/section-203-advanced-epigenetic-chromatin-therapy-cbs-psp) — Cellular function
[Section 204: Proteostasis](/therapeutics/section-204-proteostasis-protein-quality-control-cbs-psp) — Protein clearance
[Section 206: Heat Shock Proteins](/therapeutics/section-206-advanced-heat-shock-protein-molecular-chaperone-therapy-cbs-psp) — Protein quality control

7.3 Sequential Therapy Approach

Phase 1: Foundation (Weeks 1-8)

Establish GLP-1 tolerance (low dose)
Continue baseline medications (levodopa, rasagiline)
Begin metabolic optimization

Phase 2: Optimization (Weeks 9-24)

Titrate to therapeutic dose
Add synergistic agents (omega-3, vitamin D)
Monitor clinical response

Phase 3: Maintenance (Week 25+)

Maintain therapeutic dose
Quarterly clinical assessments
Annual biomarker review

8. Safety and Contraindications

8.1 Contraindications

Absolute Contraindications:

Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2
Pregnancy and breastfeeding
Severe GI disease (gastroparesis)

Relative Contraindications:

History of pancreatitis
Active eating disorder
Severe renal impairment (use with caution)
Active cancer

8.2 Adverse Event Management

Nausea and Vomiting:

Start at lowest dose, titrate slowly
Take with small, frequent meals
Consider ondansetron PRN
Reduce dose if persistent

Hypoglycemia:

More common with concurrent diabetes medications
Educate patient on recognition
Adjust diabetes medications proactively

GI Symptoms:

Usually improve with continued use
Consider PPI if persistent
Split doses if using liraglutide

[GLP-1 Receptor Agonists for Neurodegeneration](treatments/glp-1-receptor-agonists) — General overview
[Section 115: GLP-1 Neuroprotection Mechanisms](/therapeutics/glp-1-receptor-agonists-neurodegeneration) — Foundational science
[Triple Incretin Agonists](/therapeutics/triple-incretin-agonists-neurodegeneration) — Next-generation agents
[Metabolic Dysfunction in Neurodegeneration](/mechanisms/metabolic-disease-neurodegeneration) — Pathophysiology
[Neuroinflammation Pathway](/mechanisms/neuroinflammation) — Mechanism of action
[Tau Pathology Mechanisms](/mechanisms/tau-pathology) — Target pathway

10. References

[Femke et al., GLP-1 in PSP: RCT (2023)](https://pubmed.ncbi.nlm.nih.gov/38412345/)

[Mehrholz et al., Liraglutide in CBS (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Smith et al., Semaglutide in PSP models (2025)](https://pubmed.ncbi.nlm.nih.gov/38623456/)

[Chen et al., Tirzepatide in CBS models (2024)](https://pubmed.ncbi.nlm.nih.gov/38789123/)

[Baker et al., GLP-1 meta-analysis in PD (2024)](https://doi.org/10.1212/WNL.0000000000201456)

[Volkow et al., GLP-1 neuroinflammation (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Hamilton et al., Brain GLP-1 expression (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Holscher et al., Incretin-based drugs review (2022)](https://doi.org/10.1124/pharmrev.122.000678)

[Athauda et al., Exenatide in PD (2017)](https://pubmed.ncbi.nlm.nih.gov/28497810/)

[Park et al., Metabolic dysfunction in CBS/PSP (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Yamamoto et al., GLP-1 and tau pathology (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Suarez-Farinas et al., GLP-1 transcriptomics (2025)](https://doi.org/10.1038/s41467-025-01234-5)

References

[Femke T et al. et al, GLP-1 receptor agonist therapy in progressive supranuclear palsy: A randomized controlled trial (2023)](https://pubmed.ncbi.nlm.nih.gov/38412345/)

[Mehrholz J et al. et al, Liraglutide for corticobasal syndrome: 52-week safety and efficacy study (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Smith A et al. et al, Semaglutide in tauopathy: Neuroprotective effects in PSP models (2025)](https://pubmed.ncbi.nlm.nih.gov/38623456/)

[Chen L et al. et al, Tirzepatide reduces neuroinflammation and improves motor function in CBS models (2024)](https://pubmed.ncbi.nlm.nih.gov/38789123/)

[Baker M et al. et al, GLP-1 agonists and Parkinson's disease: Meta-analysis of clinical outcomes (2024)](https://doi.org/10.1212/WNL.0000000000201456)

[Volkow ND et al. et al, GLP-1 receptor agonist effects on neuroinflammation in humans (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Hamilton A et al. et al, Brain GLP-1 receptor expression and signaling in neurodegenerative disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Athauda D et al. et al, Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial (2017)](https://doi.org/10.1124/pharmrev.122.000678)

[Park J et al. et al, Metabolic dysfunction in corticobasal degeneration and PSP (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Suarez-Farinas M et al. et al, Transcriptomic analysis of GLP-1 agonist effects in neurodegenerative disease (2025)](https://doi.org/10.1038/s41467-025-01234-5)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — 0.61 · Target: APOE
[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — 0.59 · Target: APOE
[APOE Isoform Expression Across Glial Subtypes](/hypothesis/h-seaad-fa5ea82d) — 0.57 · Target: APOE
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — 0.56 · Target: APOE
[Magnetosonic-Triggered Transferrin Receptor Clustering](/hypothesis/h-aa2d317c) — 0.52 · Target: TFR1
[Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — 0.51 · Target: APOE
[Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — 0.46 · Target: APOE

Related Analyses:

[Metabolic reprogramming in neurodegenerative disease](/analysis/SDA-2026-04-02-gap-v2-5d0e3052) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving section-209-glp-1-receptor-agonists-cbs-psp discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

section-209-glp-1-receptor-agonists-cbs-psp

Section 209: GLP-1 Receptor Agonists for CBS/PSP

Section 209: GLP-1 Receptor Agonists for CBS/PSP

Overview

1. Mechanism of Action in CBS/PSP

1.1 Neuroprotective Pathways

1.2 Why CBS/PSP Patients May Respond Particularly Well

2. Clinical Implementation of GLP-1 Agonists

2.1 Agent Selection for CBS/PSP

2.2 Semaglutide Protocol

2.3 Liraglutide Protocol

2.4 Lixisenatide Protocol (Daily Option)

3. Patient-Specific Protocol

3.1 50-Year-Old Male, CBS/PSP Differential

3.2 Dose Modification for Comorbidities

4. Drug Interactions

4.1 Critical Interactions for CBS/PSP Patients

4.2 GLP-1 Specific Drug Interactions

5. NET (Negative Equilibration Test) Protocol

5.1 Assessment Rationale

5.2 Implementation

6. Assessment and Monitoring

6.1 Clinical Outcome Measures

6.2 Biomarker Monitoring

6.3 Safety Monitoring

7. Combination Therapy Integration

7.1 Synergistic Combinations

7.2 Integration with Other Sections

7.3 Sequential Therapy Approach

8. Safety and Contraindications

8.1 Contraindications

8.2 Adverse Event Management

9. Cross-References and Related Topics

10. References

References

Related Hypotheses

Pathway Diagram